Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to $71000.0.

  • Harmony Biosciences Holdings' Capital Expenditures rose 226666.67% to $71000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $716000.0, marking a year-over-year decrease of 414.99%. This contributed to the annual value of $1.2 million for FY2024, which is 26955.13% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Capital Expenditures stood at $71000.0, which was up 226666.67% from $4000.0 recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Capital Expenditures registered a high of $632000.0 during Q2 2024, and its lowest value of $3000.0 during Q3 2024.
  • Moreover, its 5-year median value for Capital Expenditures was $78500.0 (2022), whereas its average is $138071.4.
  • Data for Harmony Biosciences Holdings' Capital Expenditures shows a peak YoY increase of 246000.0% (in 2025) and a maximum YoY decrease of 9936.71% (in 2025) over the last 5 years.
  • Over the past 5 years, Harmony Biosciences Holdings' Capital Expenditures (Quarter) stood at $93000.0 in 2021, then fell by 7.53% to $86000.0 in 2022, then increased by 24.42% to $107000.0 in 2023, then skyrocketed by 379.44% to $513000.0 in 2024, then crashed by 86.16% to $71000.0 in 2025.
  • Its last three reported values are $71000.0 in Q3 2025, $4000.0 for Q2 2025, and $128000.0 during Q1 2025.